Roche Latvia

What Roche Latvia does

Roche Latvija SIA is the Latvian wholly-owned subsidiary of Swiss pharmaceutical group F. Hoffmann-La Roche Ltd, operating in Riga since its re-establishment in 1997 (the parent has had Latvian commercial presence since 1925). The entity runs three business lines: Pharmaceuticals, Diagnostics, and Roche Services & Solutions (RSS) EMEA, the last of which was established as a regional satellite office in 2023 to deliver drug-safety (pharmacovigilance), clinical-research, and back-office services to EMEA operations from a Riga base.

The Pharmaceuticals portfolio covers more than 35 marketed products spanning oncology, hematology, immunology, neuroscience, ophthalmology, virology, and nephrology, including flagship brands Herceptin, Avastin, MabThera, Ocrevus, Hemlibra, Tecentriq, and Tamiflu. The Diagnostics division distributes products such as the Accu-Chek blood-glucose monitoring line. Operating standards are aligned with EMA marketing authorizations, EU Good Pharmacovigilance Practice (GVP), the EU Clinical Trials Regulation, and GDPR.

Revenue mechanics derive from Latvian public reimbursement sales of specialty pharmaceuticals to the National Health Service (NHS) and to two anchor university hospitals — Riga East University Hospital and Paula Stradiņš Clinical University Hospital — supplemented by diagnostics device and consumable sales. The RSS EMEA business represents an internal cost-recovery or intracompany service-revenue stream tied to the parent group's EMEA headcount strategy, currently employing around 40 staff of six nationalities and planned to scale to approximately 200 over a 4–5 year horizon.

Name

Roche Latvia

Legal name

Roche Latvija SIA

Website

https://roche.lv

Company type

Private

Founded year

1997

Operating status

Operating

Short description

Roche Latvija SIA is the Riga-based Latvian subsidiary of Swiss pharma group F. Hoffmann-La Roche, operating Pharmaceuticals, Diagnostics, and Roche Services & Solutions (RSS) EMEA; it markets 35+ specialty medicines and diagnostics to Latvian hospitals and the NHS, while RSS Riga provides pharmacovigilance and clinical-research services across EMEA.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Pharmaceutical medicines
• Diagnostic solutions
• Clinical research services
• Pharmacovigilance services
• Oncology therapeutics

Headquarters

HQ city

Riga

HQ country

Latvia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Others

Revenue model

1. Pharmaceutical Products: Sale of pharmaceutical medications including treatments for oncology, hematology, rheumatology, virology, nephrology, neurology, and other therapeutic areas.
2. Diagnostic Products: Sale of diagnostic solutions and products including Accu-Chek diabetes management products.
3. Roche Services & Solutions: Business services including digital marketing, regulatory capabilities, finance, IT, procurement, and project management provided to Roche affiliates globally.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Roche Latvia is the Latvian affiliate of Swiss-based F. Hoffmann-La Roche Ltd. It develops, supplies, and distributes prescription pharmaceutical medicines (oncology, hematology, rheumatology, virology, nephrology, neurology, ophthalmology), diagnostic solutions including Accu-Chek diabetes management products, drug safety / pharmacovigilance services, clinical research services, and shared business services (Roche Services & Solutions EMEA) to other Roche affiliates.

Product overview

Roche Latvia operates as the Latvian affiliate of the global biotechnology company Roche. The product and service portfolio consists primarily of prescription pharmaceutical products (over 35 listed medications) across oncology, immunology, infectious diseases, hematology, neuroscience, and ophthalmology therapeutic areas. Key therapeutic focus areas include breast cancer, lung cancer, hemophilia A, and ophthalmology (eye diseases). The company also offers diagnostic solutions through the Diagnostics division, clinical research services, pharmacovigilance/drug safety monitoring, and business services through Roche Services & Solutions (RSS) EMEA. Major products include targeted cancer therapies (Herceptin, Kadcyla, Perjeta, Tecentriq), immunotherapies (Hemlibra, Ocrevus), and antivirals (Tamiflu). The Diagnostics division provides companion diagnostics and testing solutions that complement pharmaceutical treatments.

Differentiator

Problem solved

Functional benefit

Brands

• Accu-Chek: Diabetes management brand offering blood glucose meters, insulin pumps, and related supplies. Roche Latvija provides Accu-Chek customer support through a dedicated hotline.

Products and services

• Pharmaceutical Medicines Portfolio
• Roche Diagnostics Solutions
• Drug Safety / Pharmacovigilance Services
• Clinical Research Services
• Roche Services & Solutions (RSS) EMEA

Quantifiable outcome

• Roche provides medicines approved by European Medicines Agency and Latvian State Medicines Agency

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature3 records

Partnerships

Two partnerships are on record, tiered minor.

• Rīgas Stradiņa universitāte (RSU)minorStrategic or Co-development Partner · 2 January 2024Roche supports RSU's longitudinal anthropological research project in Piebalga, comparing pre-WWII data collected by Professor Jēkabs Prīmanis in 1936-1937 with new measurements taken in summer 2024. Project involves approximately 500 participants from Jaunpiebalga and Vecpiebalga. Roche provides funding support as part of Swiss healthcare company collaboration.
• Dekoratīvās mākslas un dizaina muzejs (Latvian National Museum of Art)minorGTM or Marketing PartnerRoche Latvia partnered with the Decorative Arts and Design Museum in Riga for the exhibition 'Courage and Care. Architecture and Design: Roche Vision' from September 13 to November 23, 2025. Exhibition showcases Roche's progressive approach to architecture and graphic design, highlighting connections between Swiss and Latvian cultural values.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Merck (MSD) Latvia: MSD Latvia markets oncology (Keytruda) and other innovative specialty pharmaceuticals through the same university hospital channels. Direct competitor in immuno-oncology and competes for the same National Health Service formulary slots as Roche's Tecentriq and related biologics.
• AbbVie Latvia: AbbVie's Latvian affiliate markets immunology, oncology, and neuroscience specialty pharmaceuticals with overlapping positioning to Roche's hematology and immunology franchises. Competes for the same hospital and reimbursement channels.
• Pfizer Latvia: Pfizer Latvia distributes innovative pharmaceuticals and vaccines through hospitals and retail pharmacies, competing directly with Roche in oncology and specialty care. Comparable business model: enterprise field sales, EMA-approved portfolio, and government-payer relationships.
• AstraZeneca Latvia: AstraZeneca Latvia sells oncology, respiratory, and cardiovascular innovative medicines through similar channels as Roche. Direct competitor in oncology biologics and small-molecule targeted therapies with overlapping hospital and National Health Service accounts.
• Sanofi Latvia: Sanofi Latvia markets innovative specialty pharmaceuticals including oncology, immunology, neurology (multiple sclerosis), and rare-disease products. Direct overlap with Roche's neurology franchise (Ocrevus vs. Sanofi's MS therapies) and immunology portfolio.
• Johnson & Johnson Innovative Medicine Latvia: J&J Innovative Medicine sells oncology and immunology biologics (Darzalex, Stelara, Tremfya) in Latvia, competing directly with Roche's hematology and immunology portfolio. Comparable enterprise sales motion and government reimbursement access requirements.
• Novartis Latvia: Novartis operates a Latvian affiliate marketing innovative specialty pharmaceuticals across oncology, neurology, and immunology. It is the most direct competitor to Roche Latvia, with overlapping therapeutic portfolios (e.g., MS, oncology, ophthalmology) and similar enterprise field-sales motion targeting the same university hospitals and National Health Service.
• Amgen Latvia: Amgen Latvia markets innovative biologics in oncology, hematology, and inflammatory diseases. Direct competitor in biosimilar and biologic specialty therapeutics with similar target customer base of Latvian university hospitals and prescribing specialists.

Broad incumbents

• Bayer Latvia: Bayer Latvia combines innovative pharmaceuticals (oncology, women's health) with consumer health and crop science. Broader incumbent with overlapping pharma presence but wider portfolio scope than Roche Latvia's specialty-pharma focus.
• GSK Latvia: GSK Latvia markets innovative specialty pharmaceuticals and vaccines. While overlapping in some specialty areas, GSK's broader portfolio across vaccines and consumer health makes it a broader incumbent rather than direct specialty competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/roche
• YouTubeyoutube.com/roche
• Facebookfacebook.com/RochepharmaLV
• LinkedInlinkedin.com/company/roche-latvia
• Instagraminstagram.com/roche

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Latvia